Royal London Asset Management Ltd. Sells 178,991 Shares of Moderna, Inc. (NASDAQ:MRNA)

Royal London Asset Management Ltd. lowered its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 52.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 160,628 shares of the company's stock after selling 178,991 shares during the period. Royal London Asset Management Ltd.'s holdings in Moderna were worth $6,679,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. State Street Corp increased its position in shares of Moderna by 12.1% in the third quarter. State Street Corp now owns 16,847,212 shares of the company's stock worth $1,125,899,000 after purchasing an additional 1,823,276 shares during the last quarter. Geode Capital Management LLC grew its stake in Moderna by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company's stock worth $470,670,000 after buying an additional 178,115 shares in the last quarter. Wellington Management Group LLP grew its stake in Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company's stock worth $349,166,000 after buying an additional 906,114 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Moderna by 0.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company's stock valued at $260,023,000 after buying an additional 19,819 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in Moderna by 6.2% in the third quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company's stock worth $205,431,000 after acquiring an additional 178,939 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. UBS Group dropped their price target on Moderna from $96.00 to $78.00 and set a "buy" rating for the company in a research note on Wednesday, February 19th. Citigroup initiated coverage on Moderna in a research report on Thursday, March 13th. They issued a "neutral" rating and a $40.00 target price for the company. Morgan Stanley reduced their price target on shares of Moderna from $70.00 to $38.00 and set an "equal weight" rating on the stock in a research report on Wednesday, January 15th. Evercore ISI set a $50.00 price objective on shares of Moderna in a report on Friday, February 14th. Finally, Barclays cut shares of Moderna from an "overweight" rating to an "equal weight" rating and cut their price objective for the company from $111.00 to $45.00 in a research note on Tuesday, February 18th. Four investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $59.00.

Moderna Trading Up 2.0 %

NASDAQ MRNA traded up $0.64 during trading on Thursday, hitting $32.12. The company had a trading volume of 6,193,251 shares, compared to its average volume of 6,669,334. The company's fifty day moving average is $34.81 and its 200-day moving average is $45.02. Moderna, Inc. has a one year low of $29.25 and a one year high of $170.47. The company has a market cap of $12.42 billion, a price-to-earnings ratio of -3.46 and a beta of 1.86.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.